Scinai Immunotherapeutics Ltd
SCNI
查看详细走势图
0.832USD
-0.018-2.17%
收盘 02/06, 16:00（美东）报价延迟15分钟
1.26M总市值
0.07市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-2.17%
5天
-15.13%
1月
+3.28%
6月
-45.28%
今年开始到现在
+16.80%
1年
-78.17%
查看详细走势图
TradingKey Scinai Immunotherapeutics Ltd股票评分
单位: USD 更新时间: 2026-02-06操作建议
Scinai Immunotherapeutics Ltd当前公司基本面数据相对稳定，最新ESG披露属于行业领先水平。增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名231/392位。机构持股占比非常高，中期看，股价处于下降通道。近一个月，市场表现较强，但基本面和技术面综合得分较低，较强的走势没有得到基本面和技术面印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Scinai Immunotherapeutics Ltd评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Scinai Immunotherapeutics Ltd亮点
亮点风险
Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
业绩增长期
公司处于发展阶段，最新年度总收入658.00K美元
业绩转盈
公司业绩转盈，最新年度盈利美元
估值合理
公司最新PE估值0.07，处于3年历史合理位
机构加仓
最新机构持股166.27K股，环比增加32.35%
活跃度降低
近期活跃度降低，过去20天平均换手率-0.81
分析师目标
根据
0
位分析师
--
评级
--
目标均价
--
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Scinai Immunotherapeutics Ltd新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Scinai Immunotherapeutics Ltd简介
Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
公司代码SCNI
公司Scinai Immunotherapeutics Ltd
CEOReichman (Amir)
网址https://www.scinai.com/
相关品种
